Allergy Immunotherapy Market Size, Share & Industry Analysis, By Type (Subcutaneous Immunotherapy, and Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma, and Others), By Distribution Channel (Hospital Pharmacies, and Retail Pharmacies & Online Pharmacies), and Regional Forecast, 2024-2032

The global allergy immunotherapy market size was valued at USD 1.70 billion in 2023 and is anticipated to grow from USD 1.84 billion in 2024 to USD 4.02 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period (2024-2032).

Allergy immunotherapy, also known as allergen desensitization, is the repeated administration of specific allergens into individuals suffering from IgE-mediated conditions. These therapies are administered in order to offer protection against the inflammatory reactions and allergic symptoms caused owing to exposure to the allergens such as pollens, house mites, insects, and others. The growing exposure to various allergens is one of the prominent factors increasing the demand for these therapies.

• According to an article published in the National Center for Biotechnology Information (NCBI) 2022, allergic rhinitis affects approximately 25% to 40% of children and adults worldwide.


• Also, according to Allergy U.K. 2023, allergic rhinitis is the common form of allergy in the U.K., affecting about 26.0% of adults and 10.0% - 15.0% of children.

Furthermore, an increase in investments by the key players to develop new immunotherapies to cater to the rising allergic population is anticipated to support the market growth. In addition, the increasing government support to provide a conducive environment to develop and launch immunotherapy products for untapped allergic conditions is augmenting the market.

• For instance, in April 2021, ALK initiated a clinical trial to study the safety and efficacy of sublingual immunotherapy tablets in children and adolescents suffering from allergic rhinitis induced by birch pollen.     

Additionally, the rising awareness among patients in various parts of the world also contributes to the global market growth during the forecast period.

The market witnessed sluggish growth during the pandemic owing to the reduction in patient visits because of the implementation of stringent lockdowns and stay-at-home rules. Furthermore, the increase in the usage of masks and restricted outdoor activities to curb the transmission of COVID-19 infection had decreased the patient’s exposure to allergens, thus reducing patient numbers and ultimately impacting the market growth.

• According to a 2022 survey published by the European Academy of Allergy and Clinical Immunology in NCBI, an estimated 93.0% of allergists observed a decline in patient visits worldwide.

However, the market is anticipated to regain normalcy in the post-pandemic era owing to the resumption of all healthcare activities.

Allergy Immunotherapy Market Trends

Shifting Preference Towards Sublingual Immunotherapy (SLIT) Tablets and Drops Aided Market Expansion

Despite subcutaneous immunotherapy (SCIT) being the gold standard for allergy treatment with high efficacy, the market is witnessing a gradual shift towards sublingual tablets and drops. Benefits such as less systemic allergic reactions and safe & easy administration of tablets compared to allergy shots have increased patient preference for sublingual over subcutaneous products.

Furthermore, due to the above-mentioned factors, there was a surge among physicians prescribing sublingual products in many countries. For instance, according to the American College of Allergy, Asthma & Immunology, approximately 73.0% of allergists in the U.S. prescribed SLIT tablets to patients suffering from allergies in the year 2019.

Moreover, the companies are also shifting their focus to develop and launch sublingual products in order to meet the growing demand for these products. The companies are also highly investing in the research and development of developing these products for various allergy types.

• For instance, in September 2021, Stellargenes Greer launched a sublingual immunotherapy tablet in Germany under the brand name Orylmyte.

Similarly, sublingual immunotherapy tablets are the preferred treatment option for people who have a single allergen that causes most of their symptoms. In addition, these medicines may provide relief from symptoms for several years after discontinuing treatment if they were taken regularly over a period of several years. This treatment can also be taken at home. Due to these advantageous factors, people are preferring sublingual immunotherapies over injectable therapies.

Allergy Immunotherapy Market Growth Factors

Growing Prevalence of Allergies to Augment the Demand for Immunotherapy Drugs

Allergic conditions adversely affect the quality of life of an individual by impairing various physiological functions. The rising prevalence of allergies among people across the globe owing to increased exposure to multiple allergens such as pollens, dust mites, molds, and others, is raising the demand for an effective treatment regimen such as allergy immunotherapy (AIT). The prevalence of allergies is growing exponentially in developing and Western countries, leading to a spike in the demand and adoption of immunotherapy.

• For instance, according to the Centers for Disease Control and Prevention, approximately 31.8% of the adult population (aged 18 years and above) in the U.S. are suffering from an allergy and around 25.7% are affected with seasonal allergies in 2023. A similar trend is likely to be observed in other countries across the globe, which will ultimately increase the demand for these products.

Additionally, the cumulative efforts by government organizations and key manufacturers to raise awareness for the proper management of allergies and develop new products to meet the rising demand are expected to augment the market growth.

• For instance, in November 2021, Angany, a Canada-based biotechnology company, agreed with Nextmune, a specialty pharma segment within Vimian Group, to develop new vaccines for treating allergies and atopic dermatitis.

RESTRAINING FACTORS

High Cost of Treatment Coupled with Poor Adherence to Medication to Impede Market Growth 

Despite the various benefits associated with allergy immunotherapy, the treatment has a low adherence among the population due to various factors such as, limited patient awareness, and lack of availability of proper reimbursement.

• For instance, according to an article published in the NCBI in 2022, the inconvenience caused by SCIT and the adverse effects associated with subcutaneous and sublingual therapy are the main reasons for discontinuing these therapies among patients.


• In addition, the cost for allergy shots in the U.S. is about USD 1,600 to USD 4,000 per year for a person with no insurance coverage and is around USD 800 per year for patients with proper reimbursement. Moreover, the SLIT drops in the country are not yet approved and are not covered under insurance.

Thus, the high cost associated with the therapy and limited insurance coverage in some countries is expected to limit the adoption of allergy immunotherapy.

Allergy Immunotherapy Market Segmentation Analysis

By Type Analysis

Subcutaneous Immunotherapy (SCIT) to Dominate the Market Owing to its High Efficacy

Based on type, the market is segmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The SCIT segment dominated the global allergy immunotherapy market share in 2023 as it is the gold standard for the treatment of allergies with high efficacy compared to SLIT therapy. Also, the launch of subcutaneous products and collaboration by the players to expand their market is expected to increase its distribution and adoption. For instance, in June 2021, Stallergenes Greer relaunched the SCIT product, Alustal, in Spain and Italy after the resumption of SCIT production in France

Also, the SLIT segment is anticipated to witness tremendous growth during the forecast period owing to the increase in product adoption because of the benefits associated with the therapy. Furthermore, the approval and launch of various SLIT products is also expected to propel the market growth.

• In January 2023, ALK received U.S. FDA approval for house dust mite allergen extract, ODACTRA, a sublingual tablet for house dust mites-induced allergic rhinitis.

By Application Analysis

Rising Prevalence of Allergic Rhinitis to Propel Market Growth

On the basis of indication, the market is categorized into allergic rhinitis, allergic asthma, and others. The allergic rhinitis segment is anticipated to dominate the market during the study period owing to the growing burden of allergic rhinitis cases.  Allergy immunotherapy is effective in achieving long-term results for allergic rhinitis.

• According to an article published in the NCBI 2022, the prevalence of allergic rhinitis is high as 30% across the globe, whereas the prevalence based on physician diagnosis is approximately 15%.

Additionally, the launch of products by key players to treat allergic rhinitis using these therapies will likely bolster market growth. In April 2021, ALK announced that FDA expanded its approval of short ragweed pollen allergen extract, Ragwitek to include treatment for children and adolescents, starting at age five years, with short ragweed pollen-induced allergic rhinitis.

Moreover, the strong pipeline of products focused on the treatment of this condition is also expected to supplement the market growth in the coming years.

• For instance, in June 2023, ALK announced the completion of the phase 3 trial of ACARIZAX for the treatment of house dust mite - induced allergic rhinitis.

Moreover, allergic asthma, and other (including food allergies, insect allergies, and others) segments are expected to witness lucrative growth in the forthcoming years. The rising investment by key players to develop AIT drugs in order to treat various allergies is one of the prominent factors contributing to market growth.

• In July 2022, Stellargenes Greer announced positive results from its real word study, EfficAPS, and confirmed the benefit of sublingual immunotherapies on the onset as well as worsening of asthma in patients.

Also, increasing regulatory approvals for medications treating food allergies is responsible for the segment’s growth.

• For instance, in February 2024, the U.S. FDA approved the Xolair (omalizumab) injection for the treatment of immunoglobulin E-mediated food allergy in certain adults and children. This medication decreases the risk of anaphylaxis occurring from accidental exposure to a variety of foods.

By Distribution Channel Analysis

On the basis of distribution channels, the market is segmented into hospital pharmacies and retail & online pharmacies. The retail and online pharmacies segment dominated the market share owing to the convenience and special discounts offered and the quality customer services provided by these distribution channels. Also, an increase in the number of retail pharmacies and patients purchasing drugs from these are anticipated to drive sales, thus leading the segment growth.

• For instance, according to the Department of Health and Human Services, in 2021, there was a 4.0% increase in sales of chain store pharmacies among all the retail pharmacies in the U.S.

The hospital pharmacies segment witnessed nominal growth during the forecast period. A large number of patient visits and the surge in the admission of allergic patients in hospitals contributed to the segment growth. Furthermore, the increasing number of hospitals across developed and developing countries and the rising prevalence of different allergic conditions drive market growth.

• According to a report published by Anaphylaxis UK in September 2022, there was an increase in hospital admissions for allergies and anaphylaxis from March 2021 to March 2022. Also, for children aged 18 and under, there was a 16.8% increase in allergy and anaphylaxis admissions in 2020-2021.

REGIONAL INSIGHTS

Europe generated a revenue of USD 1.20 billion in 2023 and will dominate the market throughout the forecast period. The rising prevalence of allergies in the region, and constant efforts by the governments and companies to develop and launch allergy immunotherapy products are the key factors promoting market growth. Also, increasing investment in research and development to manufacture these products for other allergy types such as food allergies, insect allergies, availability of proper reimbursement for the therapy in the region, and others are some factors supporting the market growth.

• For instance, in November 2021, Stellargenes Greer launched Orylmyte, a sublingual immunotherapy tablet in Belgium.

On the other hand, the market in the Asia Pacific is anticipated to grow at the highest CAGR during the forecast period. The rising burden of patients suffering from allergies, the shifting focus of key players to expand their presence in the region, and rising awareness among the population regarding the proper management of allergies are a few factors bolstering market growth.

• For instance, in March 2022, ALK-Abello submitted a registration application for sublingual allergy immunotherapy after getting regulatory approval from China. Such initiatives by companies will strengthen the market in the region.

North America market is anticipated to observe a considerable growth during the forecast period. Rise in the treatment rate in the region, increase in the adoption of novel allergy immunotherapy and  rising cases of allergies are fuelling market growth. Additionally, continuous efforts by key companies to strengthen their position in the region also support the growth of the market in the upcoming years.

Additionally, Latin America and the Middle East & Africa accounted for a comparatively less market share in 2023 and are expected to witness considerable growth during the forecast period. Increasing initiatives by the government to promote the adoption of these products in the region, and rising grants in funds to manufacture and launch such products, among others, contributed to the growth of the market.

List of Key Companies in Allergy Immunotherapy Market

ALK-Abello Dominated the Market Owing to its Strong Presence and Robust Product Portfolio

The market is semi-consolidated owing to the presence of a few players such as ALK, Stellargenes Greer, Allergy Therapeutics, and others dominating the market. ALK is the leading company and holds the lion’s share. The strong initiatives by the company to strengthen its presence outside Europe, its robust product pipeline, and investment toward research and development of subcutaneous and sublingual products for various allergens, are contributing to its revenue growth.

• For instance, the company invested around USD 105.8 million in research and development in the year 2022, which was 5% more than the previous year.

In addition, Stellargenes Greer, and Dermapharm hold the second and third position in market. The increase in strategic business activities such as collaboration, partnerships, and increased focus towards developing personalized immunotherapy specific to individuals, among others, contribute to their growth.

• For instance, in October 2021, Stellargenes Greer partnered with Aptar Pharma to develop connected devices for the delivery of allergy immunotherapy.

Some other prominent players in the market are Allergy Therapeutics, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, and others. The strong product pipeline, wide availability of products, and various strategic activities opted by these companies is expected to bolster their growth in the market in the upcoming years.

• In October 2022, Allergy Therapeutics resumed the production of its U.K. manufacturing facility.

LIST OF COMPANIES PROFILED:

• ALK (Denmark)


• Stallergenes Greer (Switzerland)


• Allergy Therapeutics (U.K.)


• HAL Allergy B.V. (Netherlands)


• HollisterStier Allergy (U.S.)


• Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China)


• LETIPharma (Spain)


• Dermapharm Holding SE (Germany)

KEY INDUSTRY DEVELOPMENTS:

• October 2023 – ALK announced the successful completion of the phase 3 trial of Itulatek for treating tree-pollen-induced allergic rhinoconjunctivitis.


• January 2023 - HollisterStier Allergy introduced its latest product innovation, Ultrafiltered Dog, in the allergy market. The product is effective in the diagnosis and treatment of dog-sensitive patients.


• October 2022 - Allergy Partners, single specialty allergy practice group collaborated with Aimmune Therapeutics to offer Palforzia, an oral immunotherapy directly to patients.


• June 2022 - ALK initiated the phase I clinical trial for its novel sublingual tablet for the treatment of peanut allergy in North America.


• March 2022 - Allergy Therapeutics collaborated with ACG Biologics to manufacture novel peanut allergy vaccine candidates.


• January 2022 - Stallergenes Greer, entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London. The collaboration will push the boundaries of allergic patient care by identifying biomarkers of AIT efficacy.

REPORT COVERAGE

The global allergy immunotherapy market report provides qualitative and quantitative insights into market analysis, market size, and growth rate for all possible segments in the market. Along with this, the report provides global overview and an elaborative analysis of regional market dynamics, market trends, and competitive landscape. Various key insights presented in the report are the prevalence of allergic rhinitis, allergic asthma – for key countries/regions, new product launches, and key recent industry developments – mergers, acquisitions, and partnerships.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 10.3% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Type Subcutaneous Immunotherapy Sublingual Immunotherapy
By Application Allergic Rhinitis Allergic Asthma Others
By Distribution Channel Hospital Pharmacies Retail Pharmacies & Online Pharmacies
By Geography North America (By Type, By Application, By Distribution Channel, By Country) U.S. Canada Europe (By Type, By Application, By Distribution Channel, By Country /Sub-Region) Germany France U.K. Italy Spain Netherlands Belgium Poland Sweden Norway Denmark Rest of Europe Asia Pacific (By Type, By Application, By Distribution Channel, By Country /Sub-Region) China India Japan Australia South Korea Southeast Asia Rest of Asia Pacific Latin America (By Type, By Application, By Distribution Channel, By Country /Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Type, By Application, By Distribution Channel, By Country /Sub-Region) GCC South Africa Rest of the Middle East & Africa